TNGX

Tango Therapeutics Inc

Add to Watchlist

Advanced Chart

6.500

-0.41(-5.933%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.9742

Open

6.910

VWAP

6.52

Vol

2.05M

Mkt Cap

723.19M

Low

6.205

Amount

13.35M

EV/EBITDA(TTM)

Total Shares

106.85M

568.22M

EV/OCF(TTM)

P/S(TTM)

31.23

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. It is also extending its target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss. It is engaged in developing two methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors: TNG462 for non- central nervous system (CNS) cancers, including pancreatic and lung cancer, and TNG456, brain-penetrant PRMT5 inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

13.06M

+12.55%

-0.200

-25.93%

5.44M

+32.15%

-0.310

-8.71%

6.23M

+15.6%

-0.325

-9.72%

Estimates Revision

The market is revising Downward the revenue expectations for Tango Therapeutics, Inc. (TNGX) for FY2025, with the revenue forecasts being adjusted by -0.6% over the past three months. During the same period, the stock price has changed by 415.87%.

Revenue Estimates for FY2025

Revise Downward

-0.6%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.16%

In Past 3 Month

Stock Price

Go Up

+415.87%

In Past 3 Month

3 Analyst Rating

84.62% Upside

Wall Street analysts forecast TNGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNGX is 12.00 USD with a low forecast of 10.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

84.62% Upside

Current: 6.500

Low

10.00

Averages

12.00

High

13.00

84.62% Upside

Current: 6.500

Low

10.00

Averages

12.00

High

13.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$13

2025-04-14

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13

2025-04-14

Reiterates

Strong Buy

Reason

Cantor Fitzgerald

Eric Schmidt

Buy

Reiterates

n/a

2024-12-05

Reason

Cantor Fitzgerald

Eric Schmidt

Price Target

n/a

2024-12-05

Reiterates

Buy

Reason

B. Riley Securities

Yuan Zhi

Strong Buy

Maintains

$16 → $8

2024-11-11

Reason

B. Riley Securities

Yuan Zhi

Price Target

$16 → $8

2024-11-11

Maintains

Strong Buy

Reason

B. Riley lowered the firm's price target on Tango Therapeutics to $8 from $16 and keeps a Buy rating on the shares. Tango reported highly anticipated results for their Phase I MTA-cooperative PRMT5 inhibitor programs, brain penetrant TNG908 and potentially best-in-class TNG462, and while TNG908 is active but not competitive, TNG908 development will be discontinued, the analyst tells investors in a research note. Tango Therapeutics is in the penalty box, as investors are losing patience and are disappointed to learn TNG908 has limited efficacy in Glioblastoma Multiforme after the trial has been running for 2.5 years, and TNG462 data remains preliminary and incomplete, the firm says, but there are silver linings that give it confidence that there is a turnaround story in play.

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$13

2024-11-08

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13

2024-11-08

Reiterates

Strong Buy

Reason

Guggenheim

Charles Zhu

Strong Buy

Maintains

$18 → $8

2024-11-07

Reason

Guggenheim

Charles Zhu

Price Target

$18 → $8

2024-11-07

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$13

2024-10-28

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13

2024-10-28

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Tango Therapeutics Inc (TNGX.O) is -4.84, compared to its 5-year average forward P/E of -5.59. For a more detailed relative valuation and DCF analysis to assess Tango Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.59

Current PE

-4.84

Overvalued PE

-2.20

Undervalued PE

-8.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.41

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.81

Undervalued EV/EBITDA

-5.63

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

21.35

Current PS

24.62

Overvalued PS

33.86

Undervalued PS

8.84

Financials

Annual

Quarterly

FY2025Q2

YoY :

-83.99%

3.18M

Total Revenue

FY2025Q2

YoY :

+38.63%

-40.97M

Operating Profit

FY2025Q2

YoY :

+52.06%

-38.85M

Net Income after Tax

FY2025Q2

YoY :

+45.83%

-0.35

EPS - Diluted

FY2025Q2

YoY :

+55.23%

-37.14M

Free Cash Flow

FY2025Q2

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q2

YoY :

+116.01%

-613.96

FCF Margin - %

FY2025Q2

YoY :

+850.07%

-1.22K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

143.2K

USD

0-12

Months

30.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

74.0K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.1M

Volume

6-9

Months

2.7M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

21.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

143.2K

USD

0-12

Months

30.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

74.0K

USD

Months

TNGX News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

07:02:35

Tango Therapeutics reports Q2 EPS (35c), consensus (34c)

2025-06-27 (ET)

2025-06-27

07:02:32

Tango Therapeutics announces first patient dosed in Phase 1/2 trial of TNG462

2025-05-21 (ET)

2025-05-21

07:08:28

Tango Therapeutics announces first patient dosed in TNG456 Phase 1/2 trial

News

9.5

08-01NASDAQ.COM

IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates

9.0

06-27Newsfilter

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

2.0

06-16Benzinga

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session